Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV

[Guest guest]

Dig Dis Sci. 2008 Nov;53(11):2999-3006. Epub 2008 Jul 10.

Predictive factors associated with the progression to hepatic failure caused by

lamivudine-resistant HBV.

Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K,

Koga H, Takao Y, Sata M.

Kurume University School of Medicine, Kurume, 830-0011, Japan.

ray@...

The aims of this study were to select the patients with a potential for

progression to hepatic failure due to lamivudine-resistant HBV and to

standardize the treatment for patients with lamivudine-resistant HBV. Patients

(n = 47) with reactivated hepatitis due to lamivudine-resistant HBV were

classified into two groups, with and without potential for progression to

hepatic failure, according to the criteria using the data of serum bilirubin

level and prothrombin activity after the reactivated hepatitis. Multivariate

analysis showed that prothrombin activity at the initiation of lamivudine

therapy was related to the deterioration of the liver function after the

emergence of lamivudine-resistant HBV (P = 0.0025, 95%CI 0.8269-0.9601). We

assume that earlier additional or substitutive treatment with other antiviral

agent, such as adefovir dipivoxil, should be recommended when the

lamivudine-resistant HBV is detected in patients with the history of

decompensated liver disease before the administration of lamivudine, even when

hepatitis has not been reactivated yet.

PMID: 18618250 [PubMed - indexed for MEDLINE]

[Guest guest]

Dig Dis Sci. 2008 Nov;53(11):2999-3006. Epub 2008 Jul 10.

Predictive factors associated with the progression to hepatic failure caused by

lamivudine-resistant HBV.

Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K,

Koga H, Takao Y, Sata M.

Kurume University School of Medicine, Kurume, 830-0011, Japan.

ray@...

The aims of this study were to select the patients with a potential for

progression to hepatic failure due to lamivudine-resistant HBV and to

standardize the treatment for patients with lamivudine-resistant HBV. Patients

(n = 47) with reactivated hepatitis due to lamivudine-resistant HBV were

classified into two groups, with and without potential for progression to

hepatic failure, according to the criteria using the data of serum bilirubin

level and prothrombin activity after the reactivated hepatitis. Multivariate

analysis showed that prothrombin activity at the initiation of lamivudine

therapy was related to the deterioration of the liver function after the

emergence of lamivudine-resistant HBV (P = 0.0025, 95%CI 0.8269-0.9601). We

assume that earlier additional or substitutive treatment with other antiviral

agent, such as adefovir dipivoxil, should be recommended when the

lamivudine-resistant HBV is detected in patients with the history of

decompensated liver disease before the administration of lamivudine, even when

hepatitis has not been reactivated yet.

PMID: 18618250 [PubMed - indexed for MEDLINE]